Frovatriptan

Template:Short description Template:Use dmy dates Template:Cs1 config Template:Main other Template:Template other{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals= | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=141731CN[C@@H]3CCc2[nH]c1ccc(C(N)=O)cc1c2C31S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1XPSQPHWEGNHMSK-SECBINFHSA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.coma604013Frovatriptan B3OralFrovaN02 | _legal_data=Rx-onlyRx-only

| _other_data=(+)-(R)-3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole

| _image_0_or_2 = Frovatriptan structure.svgFrovatriptan 3D BS.png | _image_LR =

| _datapage = Frovatriptan (data page) | _vaccine_target=_type_not_vaccine | _legal_all=Rx-onlyRx-only | _ATC_prefix_supplemental=N02 | _has_EMA_link = | CAS_number=158747-02-5 | PubChem=77992 | ChemSpiderID=70378 | ChEBI= | ChEMBL=1279 | DrugBank=DB00998 | KEGG=D07997 | _hasInChI_or_Key=yes | UNII=H82Q2D5WA7 | _hasJmol02 = |_hasMultipleCASnumbers = 158930-17-7 |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs= | _countIndexlabels= | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields=changed |verifiedrevid=461114004}}

Frovatriptan, sold under the brand name Frova, is a triptan medication developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.

Medical uses

Frovatriptan is used in the treatment of migraine.

Available forms

It is available as 2.5 mg tablets.

Contraindications

Frovatriptan should not be given to patients with:

• Ischemic heart disease
• Cerebrovascular syndrome
• Peripheral vascular disease
• Uncontrolled hypertension
• Hemiplegic or basilar migraine

Side effects

Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Pharmacology

Pharmacodynamics

Frovatriptan is a serotonin receptor agonist, with high affinity for the 5-HT_1B/1D receptors. It has no significant effects on the GABA_A mediated channel activity and benzodiazepine binding sites. Frovatriptan inhibits excessive dilation of arteries that supply blood to the head.

Pharmacokinetics

Frovatriptan has a terminal elimination half-life of approximately 26 hours, making it the longest within its class.

Society and culture

Legal status

Frovatriptan is available only by prescription in the United States and Canada.